Spiess B D
Department of Anesthesiology, University of Washington School of Medicine, Seattle, USA.
Int Anesthesiol Clin. 1995 Winter;33(1):103-13.
The PFC emulsions have had a developmental history of promise as yet unfulfilled. Today, second-generation PFC emulsions are poised with the right gas-carrying capabilities to be able to make significant contributions to oxygen transport and delivery. The dream of stable, safe, easily transportable intravenous fluid, with universal rapid application is not yet at hand. However, we appear to be a great deal closer than in the mid 1980s. If these 40% volume-to-volume emulsions prove safe, then an entirely new realm of therapeutic options will become available. Not only will the uses for trauma and acute blood loss replacement become a reality, but extremes of euvolemic hemodilution may become possible. The use of these compounds for prevention of stroke, ischemic organ salvage, and prevention of air embolism or decompression sickness are particularly exciting. It is clear from the recent developments in PFC technology that some product will come to market in the not-too-distant future. How such a PFC will be utilized as compared with hemoglobin preparations is yet to be discerned, but the two concepts are quite different. Each will have its own specific indications.
全氟碳(PFC)乳剂有着一段充满希望但尚未实现的发展历程。如今,第二代PFC乳剂具备了恰当的携气能力,能够对氧气的运输和输送做出重大贡献。稳定、安全、易于运输且能普遍快速应用的静脉输液这一梦想尚未实现。然而,我们似乎比20世纪80年代中期更接近这一目标了。如果这些体积比为40%的乳剂被证明是安全的,那么将出现一个全新的治疗选择领域。不仅创伤和急性失血补充的应用将成为现实,而且极重度等容血液稀释也可能成为可能。将这些化合物用于预防中风、挽救缺血器官以及预防空气栓塞或减压病尤其令人兴奋。从PFC技术的最新发展可以明显看出,某种产品将在不久的将来上市。与血红蛋白制剂相比,这样一种PFC将如何被使用尚待确定,但这两个概念截然不同。每种都将有其特定的适应症。